FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 39 filers reported holding FATE THERAPEUTICS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $768,000 | +76.1% | 246,126 | -4.0% | 0.07% | +34.0% |
| Q2 2016 | $436,000 | -2.9% | 256,426 | +2.8% | 0.05% | -13.1% |
| Q1 2016 | $449,000 | -62.0% | 249,374 | -28.8% | 0.06% | -47.0% |
| Q4 2015 | $1,181,000 | -30.1% | 350,306 | +10.5% | 0.12% | -22.3% |
| Q3 2015 | $1,690,000 | -14.5% | 317,088 | +3.8% | 0.15% | +5.7% |
| Q2 2015 | $1,976,000 | – | 305,481 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |